Table A1.

Efficacy by Histology and Treatment Arms

Efficacy	Arm A: Carboplatin + Pemetrexed (n = 48)		Arm B: Carboplatin + Pemetrexed + Cetuximab (n = 53)
	Squamous (n = 17)	Nonsquamous (n = 31)	Squamous (n = 18)	Nonsquamous (n = 35)
ORR, %	76	77	83	66
95% CI	50 to 93	59 to 90	59 to 96	48 to 81
Median FFS, months	15	11	9	13
95% CI	6 to NA	6 to 17	5 to 17	9 to 19
18-month FFS, %	29	29	28	36
95% CI	11 to 51	15 to 45	NA	21 to 52
Median OS, months	NA*	21	17	25
95% CI	—	14 to 34	7 to NA	14 to NA
18-month OS, %	59	58	44	56
95% CI	33 to 78	NA	22 to 65	38 to 71

Abbreviations: FFS, failure-free survival; NA, not available; ORR, overall response rate; OS, overall survival.

^*The median OS among patients with squamous histology in arm A has not been reached but is estimated to be greater than 20 months.